Paradigm Biopharmaceuticals Ltd. reported that the first subjects have been randomized and dosed in the United States (U.S.) in the PARA_OA_002 pivotal clinical trial, evaluating injectable pentosan polysulfate sodium (PPS/Zilosul®) for the treatment of pain associated with knee osteoarthritis (kOA). The first subject randomization was confirmed at Northwestern University, Chicago, by Lead Investigator, Dr. Thomas…
QUÈ TREURE D'AQUEST ARTICLE:
- reported that the first subjects have been randomized and dosed in the United States (U.
- The first subject randomization was confirmed at Northwestern University, Chicago, by Lead Investigator, Dr.
- Aquest contingut és només per a subscriptors.
